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BubR1 is an essential mitotic checkpoint protein with
multiple functional domains. It has been implicated in
mitotic checkpoint control, as an active kinase at
unattached kinetochores, and as a cytosolic inhibitor
of APC/CCdc20 activity, as well as in mitotic timing
and stable chromosome-spindle attachment. Using
BubR1-conditional knockout cells and BubR1
domainmutants, we demonstrate that the N-terminal
Cdc20 binding domain of BubR1 is essential for all
of these functions, whereas its C-terminal Cdc20-
binding domain, Bub3-binding domain, and kinase
domain are not. We find that the BubR1 N terminus
binds to Cdc20 in a KEN box-dependent manner to
inhibit APC/C activity in interphase, thereby allowing
accumulation of cyclin B in G2 phase prior to mitosis
onset. Together, our results suggest that kineto-
chore-bound BubR1 is nonessential and that soluble
BubR1 functions as a pseudosubstrate inhibitor of
APC/CCdc20 during interphase to prevent unsched-
uled degradation of specific APC/C substrates.
INTRODUCTION
The mitotic checkpoint (or spindle assembly checkpoint) is
a surveillance mechanism that inhibits sister chromatid separa-
tion until all chromosomes are correctly bioriented on the mitotic
spindle (Musacchio and Salmon, 2007). Core components of this
checkpoint, including Mad1, Mad2, Bub1, BubR1, and Bub3,
accumulate at unattached kinetochores shortly after onset of
mitosis. There, they generate a negative signal (called ‘‘wait
anaphase’’ signal) that prevents Cdc20 from activating the
anaphase-promoting complex/cyclosome (APC/C). This signal
quenches after the last sister chromatid pair becomes attached
to the mitotic spindle, allowing the activation of APC/C by
Cdc20. Once active, APC/C initiates the separation of sister
chromosomes by targeting two key substrates, cyclin B and
securin, for destruction by the 26S proteosome through
polyubiquitination.118 Developmental Cell 16, 118–131, January 20, 2009 ª2009 ElsevThe molecular basis of the Cdc20-APC/C inhibitory signals
emanated by mitotic checkpoint proteins at unattached kineto-
chores remains unclear. One hypothesis is that kinetochore-
bound mitotic checkpoint proteins provide a catalytic surface
for the structural activation of soluble mitotic checkpoint mole-
cules so that they can efficiently bind and inhibit Cdc20. This
idea is largely based on elegant structural studies showing that
Mad2 exists in two distinct conformations (reviewed by Musac-
chio and Salmon, 2007; Yu, 2006). In one conformation, known
as the closed confirmation (C-Mad2), Mad2 locks Mad1 into
a binding pocket via a mobile structure referred to as the ‘‘safety
belt’’. This mechanism ensures that Mad1 and Mad2 form
a stable complex at unattached kinetochores. In the mitotic
cytosol, Mad2 exists in an open confirmation (O-Mad2) that
does not allow it to bind Mad1 or Cdc20. Recruitment of
cytosolic O-Mad2 to C-Mad2-Mad1 at unattached kinetochores
via C-Mad2-O-Mad2 dimerization, converts O-Mad2 into
a conformer (I-Mad2) that can capture Cdc20, and thus inhibit
APC/C activity.
A less well understood Cdc20 inhibitor is the BubR1 kinase.
BubR1, like Mad2, is also present at unattached kinetochores
and in the mitotic cytosol. A ‘‘GLEBS-like’’ motif that mediates
binding to Bub3 is necessary for BubR1 accumulation at kineto-
chores in early mitosis (Wang et al., 2001). At kinetochores,
BubR1 kinase activity is turned on by microtubule motor protein
CENP-E (Mao et al., 2003, 2005). Inhibition of BubR1 kinase
activity in astrocytoma cells causes massive chromosome mis-
segregation and cell death (Kops et al., 2004), suggesting that
the enzymatic functions of kinetochore-bound BubR1 are essen-
tial for cell viability.
Like Mad2, BubR1 binds directly to Cdc20 and inhibits APC/C
activity in vitro (Tang et al., 2001). Combined, however, BubR1
and Mad2 are much more potent APC/CCdc20 inhibitors than
the individual proteins (Fang, 2002). This, together with the
discovery of an in vivo mitotic checkpoint complex (MCC) con-
sisting of Mad2, BubR1, Bub3, and Cdc20, and the demonstra-
tion that this complex strongly inhibits APC/C activity in vitro
(Sudakin et al., 2001), led to speculation that Mad2-Cdc20
complexes generated at unattached kinetochores and released
into the cytosol assemble with BubR1-Bub3 complexes to form
the ultimate cytosolic APC/C inhibitor. Yet, how BubR1-Bub3
binding to Cdc20 or Cdc20-Mad2 is regulated is unknown.ier Inc.
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BubR1 N Terminus Controls APC/C ActivityOne theory is that kinetochore-bound BubR1 or other kineto-
chore-bound proteins recruit BubR1 or BubR1-Bub3 from the
mitotic cytosol and prime these complexes for binding to
Cdc20 or Cdc20-Mad2. Alternatively, kinase-active BubR1 at
kinetochores might activate a signaling pathway that alters the
binding ability of cytosolic BubR1-Bub3 for Cdc20 or Cdc20-
Mad2.
In addition to functioning in the mitotic checkpoint, BubR1
plays a role in the timing of mitosis (Meraldi et al., 2004). This
BubR1 function involves cooperation with Mad2 and is kineto-
chore-independent, but is otherwise not understood at the
molecular level. BubR1 is further required for stable kineto-
chore-microtubule attachments (Ditchfield et al., 2003; Lampson
and Kapoor, 2005), yet how it does so remains unknown.
Inactivation ofBubR1 in mice causes early embryonic lethality,
as do null mutations in other mitotic checkpoint proteins (Ricke
et al., 2008). However, although gene knockout studies have
firmly established the essential nature of mammalian mitotic
checkpoint proteins, it remains to be determined how individual
components of this surveillance mechanism control cell viability.
Using BubR1 conditional knockout cells and a series of BubR1
mutants with one or more defective functional domains, we set
out to identify the critical functional domain(s) of BubR1 and
the mechanisms by which the kinetochore-bound and the cyto-
solic BubR1 fractions regulate the mitotic checkpoint, mitotic
timing, and kinetochore-microtubule attachment. We demon-
strate that the N-terminal Cdc20 binding domain of BubR1 is
essential for all of these functions and acts as a pseudosubstrate
for APC/CCdc20 to prevent cyclin B destruction in interphase.
RESULTS
The N Terminus of BubR1 Is Required for Cell Viability
To dissect the essential BubR1 domains, we utilized mouse
embryonic fibroblasts (MEFs) that contain BubR1 hypomorphic
(BubR1H) alleles in which exon 5 is flanked by loxP sites (Baker
et al., 2004). Our approach was to stably introduce mutant
BubR1 expression constructs into these mutant MEFs, inacti-
vate the BubR1H alleles by expression of Cre recombinase,
and then monitor cells for growth and survival in the absence
of endogenously produced full-length BubR1 protein. Initially,
we created a set of four Flag (F)-tagged BubR1 mutants, each
lacking a distinct functional domain (Figure 1A). F-BubR1(KD2)
has two point mutations (K784 > R in the ATP binding pocket
and K802 > R in the catalytic domain of the kinase domain)
that inactivate BubR1 kinase activity (Harris et al., 2005; Mao
et al., 2003; Tang et al., 2001). F-BubR1(E406K) has a point
mutation in the GLEBS motif that interrupts Bub3 binding (Harris
et al., 2005, see also Figure 2E). F-BubR1(357–1052) lacks
the N-terminal Cdc20-binding domain (Cdc20-BD1), while
F-BubR1D(525–700) lacks the C-terminal Cdc20-binding
domain (Cdc20-BD2) (Davenport et al., 2006; Tang et al.,
2001). All four mutants and full-length BubR1 were cloned into
the pMSCV-GFP retroviral vector and expressed in BubR1H/H
MEF cells, which were immortalized by homozygous p53 gene
disruption (BubR1H/H/p53/ MEFs). GFP-positive cells were
sorted by flow cytometry. There were no notable changes in
the rates of cell death and cell proliferation in BubR1H/H MEFs
expressing any of our mutant BubR1 proteins (see Figure S1Developavailable online), excluding the possibility that these mutants
interfere with cell viability in a dominant-negative fashion.
Cultures of GFP-positive cells were then infected with a Cre-en-
coding retrovirus (pMSCV-Cre/Puro) to abort expression of wild-
type BubR1 protein from the endogenous BubR1 hypomorphic
allele. Following infection, Cre-expressing cells were selected
by addition of puromycin. As expected, cells infected with empty
vector failed to proliferate after disruption of endogenous BubR1
expression and typically died within 4–6 days after Cre induction
Figure 1. Cell Growth and Survival Requires the N Terminus of
BubR1
(A) Schematic overview of wild-type and mutant BubR1 proteins.
(B) Images of BubR1H/H/p53/ MEFs containing indicated expression
constructs taken 6 days after infection with Cre retrovirus.
(C) Viability of BubR1H/H/p53/ MEFs ectopically expressing the indicated
mutant BubR1 proteins in the presence ( Cre) or absence (+ Cre) of endog-
enous BubR1.
(D) Southern blot of BubR1H/H/p53/MEFs expressing the indicated mutant
BubR1 proteins subjected to Cre-mediated disruption of endogenous
BubR1. DNA was digested with BamH1 and blots were probed with a 30
BubR1 genomic probe (Baker et al., 2004).
(E) Western blot analysis of MEFs carrying the indicated BubR1 expression
constructs. Blots were probed with the indicated antibodies. Panels labeled
aBubR1: lanes1–6wereprobedwithantibodiesagainsthBubR1(1–350)and lanes
7 and 8 with antibodies against mBubR1(382–420). Actin was used as loading
control. The genotype of MEFs in lanes 3–6 and 8 was BubR1//p53/, that
of MEFs in lane 7 was BubR1H/H/p53/.mental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc. 119
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BubR1 N Terminus Controls APC/C ActivityFigure 2. Cdc20 Binding to BubR1 N Terminus Is Sufficient for Cell Viability
(A) Schematic overview of wild-type and mutant BubR1 proteins. K, KEN box.
(B and C) Same as legends to Figures 1B and 1C, respectively.
(D) Western blot analysis of MEFs carrying the indicated BubR1 expression constructs. Blots were probed with the indicated antibodies. Actin was used as
loading control. The genotype of cells in lanes 1 and 5 was BubR1//p53/, whereas that of cells in lanes 2–4 and 6–8 was BubR1H/H/p53/.120 Developmental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc.
Developmental Cell
BubR1 N Terminus Controls APC/C Activity(Figures 1B and 1C). When wild-type Flag-tagged BubR1
(F-BubR1(1–1052)) was ectopically expressed prior to disruption
of endogenous BubR1, the cells survived and continued to prolif-
erate (Figures 1B and 1C). Cells expressing F-BubR1(KD2),
F-BubR1(E406K), or F-BubR1D(525–700) also continued to
proliferate after Cre expression, but cells expressing
F-BubR1(357–1052) died (Figures 1B and 1C). Southern blot
analysis confirmed that the hypomorphic alleles of the surviving
cells had indeed been converted into null alleles (Figure 1D).
Western blot analysis using anti-Flag antibody validated that
each mutant was accurately expressed (Figure 1E). Most flag-
tagged BubR1 proteins were quite overexpressed compared
to endogenous BubR1. However, we note that no dominant-nega-
tive effects were observed when these same proteins were overex-
pressed inBubR1+/+/p53/ MEFs (Figure S2). Furthermore, when
the cell viability analysis was repeated using nonimmortalized
BubR1H/H MEFs, once again, the only mutant that was unable to
rescue viability was F-BubR1(357–1052) (Figure S3). Together,
thesedata demonstrate thatonly the BubR1N terminus is essential
for cell viability.
The Critical Function of the BubR1 N Terminus Is Cdc20
Binding
To determine whether the N-terminal BubR1 segment containing
the Cdc20-BD1 would be sufficient for cell growth and survival,
we expressed F-BubR1(1–363) in BubR1H/H/p53/and
BubR1H/H MEFs (Figure 2A). These cells were viable in the
absence of wild-type BubR1 and able to proliferate (Figures 2B
and 2C, and Figure S3). In contrast, F-BubR1(1–218) was unable
to mediate cell growth and survival (Figures 2A–2D, and
Figure S3). To more precisely map the BubR1 region sufficient
for cell viability, we generated F-BubR1(1–322) and
F-BubR1(47–363) (Figure 2A). Both these mutants were also
unable to mediate cell growth and survival (Figures 2B–2D), indi-
cating that the entire 1–363 BubR1 segment is essential.
Next, we tested whether Cdc20 binding to the BubR1
N terminus would be a requirement for survival. As shown in Fig-
ure 2E, F-BubR1(1–363) coprecipitated with Cdc20 from mitotic
MEF extracts, and vice versa, Cdc20 coprecipitated with
F-BubR1(1–363). In contrast, F-BubR1(1–218), F-BubR1(1–
322), F-BubR1(47–363) failed to coprecipitate Cdc20 (Figure 2E).
These data demonstrate that the first 363 residues define the
boundaries of the BubR1 N-terminal Cdc20-binding domain
and that this domain is both necessary and sufficient for cell
viability. F-BubR1(357–1052), which contains the C-terminal
Cdc20 binding domain, readily precipitated with Cdc20, and
vice versa (Figure 2E). Thus, while both domains are capable
of binding Cdc20, the fact that only the N-terminal domain is
required for viability demonstrates that they are not functionally
redundant.
ScMad3p and SpMad3p, the homologs of BubR1 in S. cerevi-
siae and S. pombe, contain two evolutionarily conserved KEN
boxes, one of which is known to be required for binding to
Cdc20. Both of these KEN boxes are conserved in mouse
BubR1 and located within BubR1(1–363), one spanning aminoDevelopacids 19–21 (designated KEN19), and the other 298–300
(KEN298). To further investigate the role of Cdc20 binding in
cell survival, we produced three F-BubR1(1–363) mutants in
which these KEN boxes were mutated to AAA either individually
or in combination, and expressed them in BubR1H/H/p53/
MEFs (Figures 2A and 2D). None of the three mutants coprecipi-
tated with Cdc20 (Figure 2E), indicating that both KEN boxes
are required for Cdc20 binding in vivo. Consistent with this,
F-BubR1(1–363)KEN19AAA, F-BubR1(1–363)KEN298AAA, and
F-BubR1(1–363)KEN19+298AAA were unable to pull down Cdc20
in the reverse experiment (Figure 2E). Importantly, none of these
mutants was able to sustain cell growth and survival following
Cre expression (Figures 2B and 2C). Thus, Cdc20 binding by
the BubR1 N terminus appears to be necessary for cell viability.
Furthermore, F-BubR1(1–363) not only pulled down Cdc20,
but also Mad2 and the APC component APC6 (Figure 2E). As
expected, Bub3 did not coprecipitate because of the absence
of the GLEBS motif. F-BubR1(1–363) KEN box mutants,
F-BubR1(1–218), F-BubR1(1–322), and F-BubR1(47–363), all of
which did not interact with Cdc20, also failed to coprecipitate
Mad2 and APC6 (Figure 2E). These data suggest that the
BubR1 N terminus, Mad2, and Cdc20 form a protein complex
that can associate with APC/C.
BubR1 Kinase Activity Sustains the Mitotic Checkpoint
Earlier work has shown that the targeting of BubR1 to kineto-
chores of unattached mitotic chromosomes is dependent on
Bub3 binding (Wang et al., 2001). Consistent with this, mutant
F-BubR1(E406K), which lacks the ability to bind Bub3 (Figure 2E),
failed to accumulate at kinetochores (Figure 3A). This result,
combined with our observation that F-BubR1(E406K) rescues
cell growth and survival in the absence of endogenous BubR1,
indicates that kinetochore-associated BubR1 functions are
nonessential. Two additional results support this conclusion.
First, F-BubR1(1–363), which does not bind Bub3 (Figure 2E)
but is sufficient for cell viability, failed to accumulate at
unattached kinetochores (Figure 3A). Second, the complemen-
tary segment, BubR1(357–1052), did concentrate at kineto-
chores (Figure 3A), yet failed to rescue cells lacking endogenous
BubR1.
Both Bub1 and Mad2 properly accumulated at unattached
kinetochores of BubR1//p53/ MEFs expressing F-BubR1(1–
363) (Figures S4A and S4B), suggesting that loss of endogenous
BubR1 has no major impact on kinetochore assembly. CENP-E
levels at kinetochores were reduced in BubR1//p53/ MEFs
expressing F-BubR1(1–363) or F-BubR1(E406K), but not in those
containing F-BubR1(KD2) or F-BubR1D(525–700) (Figure S4C),
indicating that kinetochore-bound BubR1 modulates CENP-E
binding to unattached kinetochores.
To further explore the functional relevance of kinetochore-
bound BubR1, we prepared immortalized MEFs expressing
various BubR1 mutants in the absence of endogenous BubR1
and measured their mitotic checkpoint activity using a standard-
ized nocodazole-challenge assay. BubR1//p53/ MEFs
generated by transducing BubR1H/H/p53/ MEFs with Cre(E) Immunoblots of mitotic extracts of MEFs carrying the indicated BubR1 expression constructs subjected to immunoprecipitation with Cdc20 or Flag antibody,
and probed with the indicated antibodies.mental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc. 121
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BubR1 N Terminus Controls APC/C Activityretrovirus 72 hr prior to analysis (Figure S5) had only 12% of
normal mitotic checkpoint activity (Figure 3B), indicating that
there is virtually no checkpoint activity in the absence of
BubR1. F-BubR1(1–1052) fully restored the mitotic checkpoint
in these MEFs. However, F-BubR1(KD2), which binds to kineto-
chores (Figure S6), only partially restored it to 56% of normal,
indicating that BubR1 kinase activity contributes to mitotic
checkpoint signaling. We expected F-BubR1(E406K) to have
a similar corrective effect as BubR1(KD2) because activation
of BubR1 kinase activity is mediated by CENP-E at kineto-
chores. Indeed, with 49% of normal checkpoint activity,
F-BubR1(E406K) was in the same range as F-BubR1(KD2).
Failure of F-BubR1(E406K) to bind Bub3 might impair its ability
to fully inhibit APC/CCdc20 in the cytoplasm. It is conceivable
Figure 3. The Mitotic Checkpoint Has
Different Requirements for Cytosolic and
Kinetochore-Bound BubR1
(A) Immunolocalization of Flag-tagged BubR1
proteins in MEFs during prometaphase. F-
BubR1(1–1052), F-BubR1(E406K), and F-
BubR1(1–363) were expressed in BubR1//
p53/ MEFs and F-BubR1(357–1052) in
BubR1H/H/p53/ MEFs. Flag-tagged proteins
were visualized with mouse anti-FLAG antibody
and centromeres with ACA antibody. DNA was
stained with Hoechst. Bar = 10 mm.
(B) Analysis of mitotic checkpoint activity of MEFs
challenged with nocodazole or taxol. Three inde-
pendent MEF lines per genotype were challenged
with nocodazole. Error bars represent the SD (*p <
0.0001 versus BubR1+/+/p53/ MEFs [Log rank
test]). One line per genotype was challenged with
taxol.
that this potential defect contributes to
F-BubR1(E406K)’s inability to fully
correct checkpoint activity. However,
the observation that BubR1 inhibits
APC/CCdc20 equally well in vitro in
the presence or absence of Bub3 (Tang
et al., 2001) argues against this possi-
bility. As shown in Figure 3B, mitotic
checkpoint activities in response to taxol
were very similar to those seen in
response to nocodazole. Collectively,
the above data suggest that kineto-
chore-associated BubR1 kinase activity
is important for prolonged mitotic check-
point activation.
The BubR1 N Terminus Has
a Critical Role in the Mitotic
Checkpoint
To further examine the essential function
of the N-terminal Cdc20-binding domain
of BubR1, we analyzed the mitotic
checkpoint status of BubR1//p53/
MEFs expressing F-BubR1(357–1052).
Like BubR1//p53/ MEFs, these
MEFs had extremely low mitotic checkpoint activity (Figure 3B;
13% of normal). In contrast, F-BubR1(1–363) partially restored
mitotic checkpoint function in BubR1//p53/ MEFs to 43%
of normal. Expression of F-BubR1(1–363)KEN19AAA, F-BubR1(1–
363)KEN298AAA, or F-BubR1(1–363)KEN19+298AAA in BubR1//
p53/ MEFs had no such corrective effect (Figure 3B). These
data indicate that the binding of Cdc20 to the BubR1 N terminus
in the cytosol is crucial for mitotic checkpoint function.
The BubR1 N Terminus Is Required
for Chromosome-Spindle Attachment
RNA interference (RNAi) studies in human cancer cell lines have
implicated BubR1 in stable attachment of chromosomes to
spindle microtubules (Ditchfield et al., 2003; Lampson and122 Developmental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc.
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BubR1 N Terminus Controls APC/C ActivityKapoor, 2005). To determine the domain requirements for this
function, we used three different assays. First, we treated
MEFs with the proteosome inhibitor MG132 to induce meta-
phase arrest. Spindles, centromeres, and chromosomes were
then stained to examine proper chromosome alignment at the
metaphase plate by confocal microscopy. Chromosome
misalignment was observed in 7% of BubR1+/+/p53/ meta-
phases (Figures 4A and 4B). In all instances, only one or
a few chromosomes were misaligned (minor misalignment). In
contrast, 72% of BubR1//p53/ metaphases had mis-
aligned chromosomes (Figure 4B), half of which had minor
chromosome misalignments, and half of which had major chro-
mosome misalignments involving numerous chromosomes
(Figure 4A). Expression of F-BubR1(1–1052) in BubR1/
/p53/ MEFs almost completely restored proper chromo-
some alignment (13% of metaphases remained defective). F-
BubR1(1–363) also had a major corrective effect, with only
22% of metaphases expressing this mutant exhibiting chromo-
some misalignment. Importantly, all misalignments were minor.
Conversely, F-BubR1(1–363) proteins carrying KEN box muta-
tions had absolutely no corrective ability. These data suggest
that Cdc20 binding to the BubR1 N terminus is critical for
proper chromosome-microtubule attachment.
In the second assay, we monitored chromosome alignment in
the presence of MG132 by live-cell imaging. Results obtained by
this method were essentially the same as those obtained by im-
munostaining of fixed cells (Figures 4C and 4D, and Movies S1
and S2). Furthermore, analysis of BubR1//p53/ MEFs
expressing F-BubR1(357–1052) confirmed the essential role of
the N-terminal Cdc20 binding domain in chromosome-spindle
attachment (Figure 4C). F-BubR1(KD2) and F-BubR1(E406K)
both had a major corrective effect on chromosome misalignment
when expressed in BubR1//p53/ MEFs (Figure 4C).
However, these mutants were not as effective as F-BubR1(1–
1052), suggesting that BubR1 kinase activity at kinetochores
plays a contributing role in chromosome-microtubule attachment.
Third, we monitored MEFs as they progressed through mitosis
in the absence of MG132. As expected, high rates of chromo-
some misalignment were observed in BubR1//p53/ MEFs
and BubR1//p53/ MEFs expressing F-BubR1(357–1052)
or any of the F-BubR1(1–363) KEN box mutants (Figure 4E).
Percentages of cells with major alignment problems were similar
to those seen in the presence of MG132. Most of these cells
underwent mitotic catastrophe and died within 8 hr (Figure 4E
and Movie S3). However, percentages of cells with minor align-
ments were considerably lower in the absence than in the pres-
ence of MG132, suggesting that metaphase arrest facilitated
the detection of these defects. Misalignments were rare and
minor when F-BubR1(1–1052) was present. F-BubR1(1–363),
F-BubR1(KD2), and F-BubR1(E406K) also showed no major
misalignment problems but slightly increased rates of misalign-
ment of one or a few chromosomes (Figure 4E), underscoring
that kinetochore-bound BubR1 has a contributing rather than
a critical role in chromosome-spindle attachment. No cell death
was observed among cells with minor defects (Figure 4E). We
found that Cre recombinase expression per se did not cause
chromosome misalignment (Figure S7).
F-BubR1(KD2) can only partially correct the chromosome
alignment and mitotic checkpoint defects of BubR1//p53/DevelopMEFs. It cannot be excluded that this is due to the relatively
low levels of F-BubR1(KD2) expression (Figure 1E). However,
this is unlikely because both defects were corrected when
BubR1//p53/ MEFs expressed F-BubR1(1–1052) at
F-BubR1(KD2) levels (Figure S8).
The BubR1 N Terminus Regulates Mitotic Timing
Depletion of BubR1 in HeLa cells shortens the NEBD-anaphase
time interval from about 25 to 14 min (Meraldi et al., 2004), suggest-
ing that BubR1 is a regulator of mitotic timing. This BubR1 function
isconserved inMEFs,aswe found the time fromNEBDtoanaphase
onset to be significantly reduced in BubR1//p53/ MEFs
(Figure 4F). Notably, expression of F-BubR1(1–363), but not
F-BubR1(357–1052) or F-BubR1(1–363) fragments containing
KEN box mutations, fully restored proper timing of mitosis in
BubR1//p53/ MEFs, indicating that BubR1 regulates mitotic
timing through direct Cdc20 binding in the mitotic cytosol
(Figure 4F). F-BubR1(KD2), F-BubR1(E406K), and F-BubR1D(525–
700) all restored normal NEBD-to-anaphase duration in BubR1//
p53/MEFs, confirming that the N-terminal Cdc20 bindingdomain
is the only BubR1 domain relevant to mitotic timing.
The BubR1 N Terminus Prevents Premature
Degradation of Cyclin B by APC/CCdc20
The demonstration that KEN boxes in the BubR1 N terminus are
necessary for Cdc20 binding suggests that BubR1 acts as
a pseudosubstrate inhibitor of APC/CCdc20 in early mitosis. To
test this further, BubR1//p53/ MEFs expressing various
BubR1 mutants were immunostained for cyclin B, a substrate
that is normally targeted for degradation by APC/CCdc20 in late
metaphase. As shown in Figures 5A and 5B, cyclin B levels in
prophase were 3- to 4-fold lower in BubR1//p53/ MEFs
than in BubR1+/+/p53/ MEFs. This decline is due to increased
proteosomal degradation rather than reduced gene transcrip-
tion, as MG132 treatment restored normal cyclin B protein levels
in BubR1//p53/ prophases (Figures 5C and 5D). Expres-
sion of F-BubR1(1–363), but not of F-BubR1(357–1052) or
F-BubR1(1–363)KEN19+298AAA, fully restored cyclin B levels in
prophase (Figures 5A and 5B), indicating that the N-terminal
Cdc20-binding domain indeed functions as a potent inhibitor
of cyclin B polyubiquitination in early mitosis.
Premature sister chromatid separation (PMSCS), which is
an indicator of premature APC/C activity (Baker et al., 2005),
was extremely high inBubR1//p53/MEFs, with 72% of meta-
phase spreads showing the defect (Figure 5E). When cells were
briefly treated with MG132, this percentage reduced to 48%, con-
firming that the observed separation defect was, at least in part,
due to premature APC/C activity. PMSCS was only 9%
in BubR1//p53/ MEFs when F-BubR1(1–363) was present,
and 1% when full-length BubR1 was expressed (Figure 5E). F-
BubR1(357–1052) and F-BubR1(1–363)KEN19+298AAA were unable
to rescue the PMSCS phenotype. Thus, the above data support
our conclusion that the BubR1 N terminus binds to Cdc20 and
inhibits APC/C activity.
BubR1 N Terminus Prevents Cyclin B Degradation
by APC/CCdc20 in Interphase
To further examine the degradation of cyclin B in the absence of
BubR1, we transiently transfected cyclin B-GFP (Hagting et al.,mental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc. 123
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BubR1 N Terminus Controls APC/C Activity2002) into BubR1//p53/ and BubR1+/+/p53/ MEFs and
tracked its level of expression by live-cell imaging (Figure 6A).
Cyclin B associates with centrosomes (Bailly et al., 1992),
a feature that we utilized to screen for cells in G2 phase.
BubR1+/+/p53/ MEFs in G2 typically had high cytoplasmic
levels of cyclin B-GFP (Figure 6A, and Movie S4). At mitosis
onset, cyclin B-GFP entered the nucleus and then diffused into
the mitotic cytosol after NEBD. Following proper chromosome
alignment in metaphase, cyclin B-GFP was promptly degraded,
allowing anaphase onset. BubR1//p53/ MEFs, on the other
hand, failed to accumulate high levels of cyclin B-GFP in G2
phase (Figure 6A, and Movie S5). This was due to proteosomal
degradation rather than impaired synthesis, as cyclin B-GFP
increased to normal levels after MG132 treatment (Figure 6B,
and Movies S6 and S7), suggesting that, in G2 phase, cyclin
B-GFP is marked for destruction by APC/C when BubR1 is
lacking. Consistent with this, expression of nondegradable
cyclin B-GFP containing a R42A substitution in the destruction
box of cyclin B (Clute and Pines, 1999) was high in both
BubR1+/+/p53/ and BubR1//p53/ G2 MEFs (Figure 6C).
Cyclin BR42A-GFP levels remained high as these cells entered
mitosis and arrested in metaphase. Furthermore, F-BubR1(1–
363), but not F-BubR1(1–363)KEN19+298AAA, restored normal G2
cyclin B-cerulean levels in BubR1//p53/ MEFs (Figure 6D,
and Movie S8), confirming that Cdc20 binding by the N terminus
of BubR1 prevents APC/C-mediated destruction of this cyclin.
Securin and cyclin A were not prematurely degraded in G2 or
M phase in the absence of BubR1 (Figure S9, and Movies S9
and S10), suggesting that BubR1 is a rather specific pseudosub-
strate inhibitor for cyclin B, at least in MEFs. Earlier biochemical
studies showing that securin is not prematurely degraded in
BubR1 hypomorphic cells support this notion (Jeganathan
et al., 2005). Live-cell imaging revealed that the median time
interval from G1/S to mitosis was substantially longer in
BubR1//p53/ MEFs than in BubR1+/+/p53/ MEFs
(12.3 hr versus 9.5 hr), indicating that cyclin B hypomorphism
may delay progression to mitosis (Figure S10).
Endogenous BubR1 Interacts with Cdc20 in Interphase
The above experiments suggested that the BubR1 N terminus
stabilizes cyclin B in G2 by acting as a pseudosubstrate for
APC/CCdc20. This model predicts that BubR1 forms a complex
with Cdc20 not only in mitosis, but also in interphase. To test
this, we prepared extracts from BubR1+/+ MEFs in G2 or prome-
taphase for coimmunoprecipitation experiments. To ensure thatDevelopG2 extracts were devoid of mitotic cells, any such cells were
removed from the cultures by shake-off prior to harvest. Analysis
of Hoechst-stained cells revealed that the G2 and prometaphase
samples contained 0% and 95% mitotic cells, respectively (Fig-
ure 7A). G2 and prometaphase extracts were prepared from
equal amounts of cells (Figure 7B). As shown in Figure 7C,
Cdc20 precipitated with BubR1 from both MEF extracts. Bub3
and Mad2 also precipitated with BubR1 from both G2 and mitotic
extracts, as did the APC/C component APC6 (Figure 7C). More
Cdc20, Bub3, and Mad2 precipitated from mitotic extracts,
which may be due to the fact that more BubR1 precipitated
from these extracts then from G2 extracts. Furthermore,
F-BubR1(1–363) precipitated Cdc20, Mad2, and APC6, not
only from mitotic MEF extracts (Figure 2E), but also from G2
extracts containing 0% mitotic cells (Figure 7D). Together, these
results indicate that BubR1 binds to Cdc20 and other MCC
components not only in mitosis when the mitotic checkpoint is
active, but also in interphase. We found that 80%–90% reduc-
tion of Mad2 levels in BubR1+/+/p53/ MEFs by shRNAmir
(Figure 7E and Figure S11) had no impact on cyclin B-GFP
accumulation in G2 phase (Figure 7F), indicating that BubR1 is
the primary inhibitor of APC/CCdc20-mediated cyclin B in
interphase.
DISCUSSION
Inhibition of APC/CCdc20 in Interphase by BubR1
In mitosis, BubR1 is believed to bind and inhibit APC/CCdc20 in
a mitotic checkpoint-dependent fashion (Musacchio and
Salmon, 2007). Here we provide several lines of evidence to
suggest that BubR1 functions as a pseudosubstrate inhibitor
of APC/CCdc20 in interphase to allow for cyclin B accumulation
prior to mitosis onset (Figure 7G). First, cells lacking BubR1
have strongly reduced cyclin B levels in G2, a defect that can
be restored by inhibition of the proteosome or by mutation of
the APC/CCdc20 recognition site of cyclin B. Second, the N-
terminal Cdc20 binding domain is necessary and sufficient to
prevent cyclin B degradation by APC/C in G2 phase. Third, the
BubR1 N-terminal Cdc20 binding domain harbors two KEN
boxes, mutation of which perturbs Cdc20 binding to the
BubR1 N terminus and causes premature cyclin B destruction
in G2. These KEN boxes are conserved in fission and budding
yeast Mad3p, where they are known to serve as Cdc20p binding
sites that compete with APC/C substrates for Cdc20p binding
(Burton and Solomon, 2007; King et al., 2007; SczanieckaFigure 4. The BubR1 N Terminus Regulates Chromosome-Spindle Attachment and Mitotic Timing
(A) Cdc20 binding to the BubR1 N terminus is essential for chromosome alignment. MEFs were treated with 10 mM MG132 for 2 hr, fixed and immunostained for
a-tubulin and centromeres. The second and third image from the left represent BubR1//p53/ metaphases with minor and major misalignment phenotypes,
respectively. Bar = 10 mm.
(B) Quantification of chromosome misalignment defects of MEFs shown in (A). MEF genotypes and BubR1 expression constructs are as indicated in (C). Shaded
and nonshaded areas represent major and minor misalignments, respectively.
(C) Quantification of misalignment defects in MG132-treated MEFs by live-cell imaging. Shaded and nonshaded areas represent major and minor misalignments,
respectively.
(D) Examples of metaphase-arrested MEFs displaying proper chromosome alignment (top), minor misalignment (middle), or major misalignment (bottom). Cells
were MG132-treated. Arrows designate misaligned chromosomes. Bar = 10 mm.
(E) Analysis of chromosome misalignment and cell death by live-cell imaging. We note that nearly all cells dying within 8 hr after mitosis had major alignment
defects.
(F) Timing of anaphase onset. Three MEF lines were used per genotype. Error bars represent the SD (*p < 0.0001 versus BubR1+/+/p53/ MEFs [Mann-Whitney
test]).mental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc. 125
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and ectopically expressed F-BubR1(1–363) interact with
Cdc20 not only in mitosis, but also in G2 phase.
Our binding studies in MEFs suggest that Cdc20, BubR1,
Bub3, and Mad2 already exist as a complex during interphase,
which is consistent with an earlier study in HeLa cells (Sudakin
et al., 2001). These findings imply that the MCC complex can
Figure 5. Binding of BubR1 N Terminus to
Cdc20 Inhibits APC/C Activity
(A) Prophases stained for cyclin B, phosphohi-
stone H3Ser10 (P-H3), and DNA (Hoechst).
(B) Quantification of cyclin B levels in prophase.
Error bar represents SD.
(C) Representative prophases treated with 10 mM
MG132 1 hr prior to staining for cyclin B, P-H3,
and DNA (Hoechst).
(D) Quantification of cyclin B levels in prophase
after MG132 treatment. Error bar represents SD.
(E) Incidence of PMSCS in MEFs expressing the
indicated BubR1 mutants.
assemble in a checkpoint-independent
manner. Further evidence for this notion
is provided in this issue of Developmental
Cell, where Kulukian et al. (2009) demon-
strate that functional MCC complexes
can assemble in vitro from recombinant
Mad2, BubR1, Bub3, and Cdc20 proteins
in the absence of active kinetochores,
although at much lower rates than in their
presence. One possibility is that, unlike
interphase, mitosis requires catalysis of
MCC formation by unattached kineto-
chores to offset mechanisms such as
Cdc20 ubiquitination by UbcH10 that
drive cells into anaphase by displacing
Mad2 and BubR1-Bub3 from Cdc20
(see Figure 7G; Reddy et al., 2007; Steg-
meier et al., 2007).
Although Bub3 forms a complex with
BubR1 in interphase, our finding that
BubR1 mutants that cannot interact with
Bub3 have normal cyclin B stability and
Cdc20 binding indicates that Bub3 is
not essential for BubR1’s role in inhibiting
APC/CCdc20 in interphase and mitosis.
The same may hold true for Mad2 as we
find that its depletion from MEFs by
RNAi has no impact on cyclin B stability
in interphase. A recent study showing
that cyclin B levels are normal as fly cells
lacking Mad2 enter mitosis (Buffin et al.,
2007) supports this notion.
An earlier study demonstrated that
Emi1 functions as a substrate inhibitor
of APC/CCdh1 during interphase, allowing
for cyclin A accumulation from G1/S
through early mitosis (Miller et al., 2006).
Thus, pseudosubstrate inhibition of APC/C activity seems to
be a more general mechanism through which cyclins accumulate
in interphase, with Emi1 and BubR1 inhibiting APC/CCdh1 and
APC/CCdc20 activity, respectively. Cyclin B is rather selectively
targeted for destruction by the APC/C when BubR1 is lacking,
as cyclin A and securin are stable under these circumstances.
This result is consistent with previous work on Rae1/Nup98126 Developmental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc.
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than APC/CCdc20, targets securin for destruction in early mitosis
(Jeganathan et al., 2005). It will be interesting to test in future
experiments to what extent cyclin B instability drives the mitotic
defects associated with BubR1 deficiency.
Critical BubR1 Function Is to Bind and Inhibit Cdc20
In contrast to BubR1, ScMad3p and SpMad3p are not essential
for cell viability (Hardwick et al., 2000; Millband and Hardwick,
2002). Structurally, BubR1 differs quite extensively from the
yeast Mad3p proteins (Musacchio and Salmon, 2007). The
Mad3p proteins are much smaller than BubR1, lacking
a BubR1 kinase domain and C-terminal Cdc20 binding domain.
ScMad3p contains a GLEBS-like motif required for Bub3
binding, but SpMad3p lacks this motif. One hypothesis for why
BubR1 is essential and Mad3p proteins are not is that by gaining
additional domains, BubR1 acquired additional functions, some
of which might be required for viability. In this light, it is surprising
that the only domain that is completely conserved among Mad3p
and BubR1 proteins, the N-terminal Cdc20 binding domain,
turns out to be the essential BubR1 functional domain. One plau-
sible explanation for this apparent paradox might be that the
BubR1 N terminus is implicated in a wider variety of mitotic
processes than ScMad3p and SpMad3p. Indeed, the BubR1
N terminus is critical for mitotic checkpoint function, mitotic
timing, and proper alignment of chromosomes at the metaphase
plate, while ScMad3p and SpMad3p have only been implicated
in the mitotic checkpoint. Interestingly, our live-cell imaging
experiments revealed a strong link between severe chromosome
misalignment and cell death in BubR1 null cells, indicating that
the function of BubR1 in chromosome-spindle attachment is
perhaps the most critical BubR1 function with respect to cell
viability.
How does the N-terminal Cdc20 binding domain regulate
microtubule-kinetochore attachment? As this domain functions
to inhibit APC/CCdc20 away from kinetochores, it is reasonable
to assume that it does so indirectly by preventing ubiquitination
of specific APC/C substrates that might control this process.
This seems inconsistent with the observation that attachment
defects persist when cells lacking BubR1 are treated with
MG132. However, proteosomal inhibition does not exclude
a scenario in which polyubiquitination per se is sufficient to alter
substrate activity.
Mad2 and BubR1 both regulate the timing of mitosis in a kinet-
ochore-independent fashion (Meraldi et al., 2004). It has been
proposed that this timing function requires Mad2 and BubR1
binding to Cdc20 at the onset of mitosis when checkpoint
proteins have yet to assemble at kinetochores and the check-
point is unable to protect APC/C substrates from degradation
by APC/C activity (Meraldi et al., 2004; Musacchio and Salmon,
2007). That Mad2 and BubR1 bind to Cdc20 in a kinetochore-
independent manner and that the N-terminal Cdc20 binding
domain can restore proper mitotic timing when endogenous
BubR1 is lacking, as reported here, is in support of this model.
Role of BubR1 Kinase Activity at Mitotic Kinetochores
The discovery that kinetochore-bound Mad2 converts cytosolic
Mad2 to a conformer that is able to interact with Cdc20 led to
speculation that kinetochore-bound BubR1 might likewise primeDevelopsoluble BubR1 for binding to Cdc20 or Cdc20-Mad2 (Kops et al.,
2005; Mao et al., 2003). However, our finding that BubR1
mutants that fail to localize to kinetochores can bind to Cdc20
and efficiently inhibit APC/C activity strongly suggests that
cytoplasmic BubR1 is functionally independent of kinetochore-
associated BubR1.
What then is the role of BubR1 at kinetochores? Although cells
expressing mutant BubR1 proteins that cannot bind to kineto-
chores are capable of activating the mitotic checkpoint in the
presence of nocodazole, the time interval of their arrest is
considerably shortened. This suggests that kinetochore-bound
BubR1 plays a role in sustaining mitotic checkpoint activity
under conditions where chromosome-spindle attachment prob-
lems persist for extended periods of time (Figure 7G). Impor-
tantly, cells expressing kinase-dead BubR1 showed the exact
same phenotype, implying that prolonged checkpoint signaling
requires BubR1 kinase activity at kinetochores. The observation
that combined loss of both kinetochore binding ability and kinase
activity compromises checkpoint maintenance to a similar
degree as the corresponding single mutations further supports
this notion. It will be important in future experiments to identify
the substrate(s) through which kinetochore-bound BubR1 acts
to maintain the mitotic checkpoint.
Although BubR1 mutants lacking kinase activity or Bub3
binding ability (or both) corrected nearly all major chromosome
alignment defects of BubR1 null cells, none of these mutants
was capable of reducing the minor alignment defects to the
same extent as full-length BubR1, indicating that BubR1 kinase
activity at kinetochores contributes to stable kinetochore-
microtubule attachment during metaphase.
EXPERIMENTAL PROCEDURES
Generation and Culture of MEFs
BubR1H/H MEFs and BubR1H/H/p53/ MEFs were generated and cultured as
previously described (Baker et al., 2004). For studies reported here, at least
three independently generated MEF lines per genotype were used, unless
noted otherwise. G2 phase MEFs were prepared by arresting them at the
G1/S border (using a double thymidine block) and then releasing them in
DMEM/10% FCS for 8 hr. The shake-off method was used to remove any
mitotic cells from culture flasks prior to cell harvest. Mitotic MEFs were
prepared by culturing cells for 5 hr in medium containing nocodazole
(100 ng/ml; Sigma-Aldrich) and harvesting cells by shake-off.
Expression Plasmids
A full-length cDNA clone of mouse BubR1 was used as a template for PCR to
create mutant BubR1 cDNAs (Davenport et al., 2006; Harris et al., 2005). Each
mutant was provided with an aminoterminal FLAG epitope tag and cloned into
the MluI site of the retroviral expression plasmid pMSCV-IRES-GFP. pMC-Cre
was used as a template for PCR to create pMSCV-Cre/Puro. Procedures for
viral transduction and Mad2 silencing by TRIPZ lentiviral inducible shRNAmir
(Open Biosystems) are described in detail in the Supplemental Experimental
Procedures.
Western Blotting, Coimmunoprecipitation, and Indirect
Immunofluorescence
Western blot analyses, coimmunoprecipitations, and indirect immunofluores-
cence were performed as previously described (Kasper et al., 1999). For
a-tubulin stainings, cells were incubated in PHEM buffer (25 mM HEPES,
10 mM EGTA, 60 mM PIPES, 2 mM MgCl2, [pH 6.9]) and fixed in ice-cold meth-
anol for 10 min. A Zeiss LSM 510 laser scanning microscope with a c-Apochro-
mat 1003 oil immersion objective was used for image acquisition. For
quantification of cyclin A and B levels, at least 10 cells per mitotic stagemental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc. 127
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(A) BubR1//p53/ MEFs have low cyclin B-GFP levels in G2 and mitosis. Cyclin B-GFP fluorescence of MEF cells of the indicated genotypes was measured
and the average fluorescence intensity in G2, prophase (P), prometaphase (PM), metaphase (M), and anaphase (A) plotted (n > 10 cells per genotype). Error bars
represent the SD (*p < 0.0001 versus BubR1+/+/p53/ MEFs at the same cell cycle stage [Mann-Whitney test]). Bar = 10 mm.
(B) MG132 treatment of BubR1//p53/ MEFs restores normal cyclin B-GFP expression during G2 and mitosis. Error bars represent the SD (*p < 0.0001 versus
BubR1+/+/p53/ MEFs at the same cell cycle stage [Mann-Whitney test]). Bar = 10 mm.
(C) BubR1//p53/ MEFs express normal levels of nondegradable cyclin BR42A-GFP G2 and mitosis. Error bars represent the SD.128 Developmental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc.
Developmental Cell
BubR1 N Terminus Controls APC/C ActivityFigure 7. BubR1 Interacts with APC/CCdc20
in Interphase Cells
(A) Percentage of mitotic cells present in G2 and
mitotic BubR1+/+/p53/ MEF extracts used in
coimmunoprecipitation experiments shown in (C).
(B) Western blot analysis of G2 and mitotic
BubR1+/+/p53/ MEF extracts for actin. Five
microliters of extracts used in (C) was loaded in
each lane.
(C) Cdc20 binds to BubR1 in both interphase and
mitosis. G2 and mitotic MEF extracts prepared
from equal amounts of cells were subjected to
immunoprecipitation with anti-BubR1 antibody
and probed with the indicated antibodies.
(D) As in (C), but with G2 extracts from BubR1
//
p53/ MEFs expressing BubR1(1–363).
(E) Western blot analysis showing that BubR1+/+/
p53/ MEFs transduced with pTRIPZ lentivirus
expressing mMad2-shRNAmir clone V2MM_6980
contain 10%–20% of normal Mad2 levels after
3 days of culture in medium with 1 mg/ml DOX.
(F) Mad2 depletion in BubR1+/+/p53/ MEFs has
no impact on cyclin B-GFP levels in G2 and mitosis.
DOX was added 72 hr prior to analysis of cyclin
B-GFP stability. Error bars represent the SD.
Bar = 10 mm.
(G) Model for BubR1 function in G2 phase and
mitosis. BubR1 binds to Cdc20 or Cdc20 already
bound to APC/C (probably in combination with
Mad2 and Bub3) in a KEN box-dependent manner
in G2, thereby blocking access of cyclin B to the
APC/C, allowing this cyclin to accumulate and
perform its mitotic functions. In mitosis, mitotic
checkpoint proteins accumulating at unattached
kinetochores catalyze binding of Mad2 and
BubR1-Bub3 to Cdc20 that might emerge due to
degradation of APC/CCdc20 inhibitors, such as
Emi1 (Miller et al., 2006), and/or activation of
mechanisms that displace Mad2 and BubR1
from Cdc20 in mitosis, such as UbcH10-mediated
ubiquitination of Cdc20. BubR1 kinase activity is
critical for APC/C inhibition under circumstances
where spindle damage persist for prolonged
periods of time.were analyzed per MEF line. The mean fluorescence intensity was determined
after background subtraction of images transformed to 8 bits grayscale, using
NIH Image J software. A list of antibodies used is provided in Supplemental
Experimental Procedures.
Live-Cell Imaging
Nocodazole-challenge assays were performed as follows. MEFs were first
transduced with a retrovirus encoding a monomeric red fluorescent protein
(mRFP)-tagged H2B to allow visualization of chromosomes by fluorescence
microscopy. Cells were then seeded onto 35 mm glass-bottomed culture
dishes (MatTek Corporation) and cultured in DMEM/10% FBS. Approximately
24 hr later, experiments were performed using a Zeiss Axio Observer Z1
system with: CO2 Module S, TempModule S, Heating Unit XL S, Pln Apo
633/1.4 oil DICIII objective, AxioCam MRm camera, and AxioVision 4.6 soft-
ware. The imaging medium was DMEM/10% FBS. The temperature of the
imaging medium was kept at 37C. The exposure times in nocodazole-
challenge experiments were identical among experiments. Nocodazole wasDevelopadded to a final concentration of 100 ng/ml. Cells undergoing nuclear envelope
breakdown (NEBD) were marked and monitored at 15 min intervals to deter-
mine when they decondensed their chromosomes. The duration of arrest in
mitosis, which is defined as the interval between NEBD (onset of mitosis)
and chromatin decondensation (exit from mitosis without cytokinesis), was
then calculated and plotted. The time at which 50% of the cells had exited
mitosis was used for comparison. Mitotic checkpoint activities of BubR1//
p53/ MEFs and BubR1//p53/ MEFs expressing BubR1 mutants were
normalized to BubR1+/+/p53/ MEFs for comparison (Jeganathan et al.,
2007). Taxol-challenge experiments were essentially the same except that,
instead of nocodazole, taxol (Sigma Aldrich, T1912) was added at a concentra-
tion of 1 mM.
In mitotic timing experiments, the time interval between NEBD and
anaphase onset was measured as H2B-mRFP positive cells progressed
through an unchallenged mitosis. Interframe intervals were 3 min. To deter-
mine the time interval between G1/S and mitosis onset, H2B-mRFP-positive
cells were seeded onto 6-well plates and infected with pMSCV-Cre retrovirus.(D) Expression of F-BubR1(1–363) inBubR1//p53/ MEFs restores normal cyclin B-cerulean levels in G2 and mitosis, whereas F-BubR1(1–363) lacking its KEN
boxes does not. Error bars represent the SD (*p < 0.0001 versus BubR1+/+/p53/ MEFs at the same cell cycle stage [Mann-Whitney test]). Bar = 10 mm.mental Cell 16, 118–131, January 20, 2009 ª2009 Elsevier Inc. 129
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(Sigma-Aldrich, A0781) to the culture medium. After 15 hr, cells were washed
three times with PBS, released in fresh prewarmed culture medium, and
monitored at 15 min intervals for mitosis entry (chromosome condensation).
Cumulative frequency plots for G1/S-to-mitosis times were generated for
each cell line. Median values were calculated and used for comparison.
To measure chromosome alignment, MEFs were treated with 10 mM MG132
(Sigma Aldrich, C2211). After 30 min, 20–30 cells entering prophase were
marked and, 30 min later, analyzed for chromosome alignment defects. Cells
exhibiting 1–3 misaligned chromosomes were classified as cells with minor
misalignment defects, whereas those with four or more misaligned chromo-
somes were classified as cells with major misalignment defects.
Analyses of fluorescent protein-tagged cyclin B and securin levels were as
follows: H2B-mRFP expressing MEFs were infected with pMSCV-Cre/Puro
for 48 hr and Cre-expressing MEFs were selected in culture medium contain-
ing 3 mg/ml puromycin for 36 hr. Cells were harvested and nucleofected with
5 mg pCMX-Cyclin B1-GFP, 3 mg pCMX-Cyclin B1R42A-GFP, 5 mg pCeru-
lean-N1-Cyclin B1, or 2 mg pEYFP-N1-Securin plasmid DNA (kindly provided
by Jonathon Pines, Gurdon Institute, Cambridge, United Kingdom) using an
Amaxa Nucleofector II. Cyclin B-cerulean was used instead of cyclin B-GFP
in instances where MEFs were already GFP-positive, such as BubR1//
p53/ MEFs expressing BubR1(1–363) or BubR1(1–363)KEN19+298AAA. Two
x106 MEFs were used per nucleofection. Nucleofections were done in MEF2
buffer (Amaxa, VPD-1005). MEFs were immediately seeded into 35 mm dishes
and analyzed 4 hr later. G2 phase cells were marked and images acquired
every 6 min. In specified experiments, we inhibited the proteosome by adding
10 mM MG132 to the imaging medium. Exposure times were identical among
experiments for each fluorochrome/filters set. For quantification of fluores-
cence levels, at least 10 cells were analyzed per MEF line. The mean fluores-
cence intensity at each cell stage was determined, after background subtrac-
tion of images transformed to 8 bits grayscale, using NIH Image J software
(http://rsb.info.nih.gov/ij/). Mean fluorescence intensities were expressed in
arbitrary units. For each of the aforementioned experiments, at least three
independent MEF lines were used per genotype unless otherwise noted.
GraphPad Prism software was used for statistical analyses. To study the
impact of Mad2 depletion on cyclin B-GFP stability, BubR1+/+/p53/ MEFs
containing mMad2-shRNAmir clone V2MM_6980 were grown in the presence
or absence of 1 mg/ml doxycycline for 72 hr prior to nucleofection with pCMX-
Cyclin B1-GFP.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, eleven
figures, and ten movies and can be found with this article online at http://
www.cell.com/developmentalcell/supplemental/S1534-5807(08)00478-4/.
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